Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 13.51
NVIV's Cash to Debt is ranked lower than
56% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. NVIV: 13.51 )
Ranked among companies with meaningful Cash to Debt only.
NVIV' s 10-Year Cash to Debt Range
Min: 0.11  Med: 54.49 Max: No Debt
Current: 13.51
F-Score: 2
Z-Score: 2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -303.70
NVIV's ROE (%) is ranked lower than
94% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. NVIV: -303.70 )
Ranked among companies with meaningful ROE (%) only.
NVIV' s 10-Year ROE (%) Range
Min: -775.86  Med: -546.32 Max: -195.09
Current: -303.7
-775.86
-195.09
ROA (%) -156.05
NVIV's ROA (%) is ranked lower than
90% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. NVIV: -156.05 )
Ranked among companies with meaningful ROA (%) only.
NVIV' s 10-Year ROA (%) Range
Min: -1218.1  Med: -266.67 Max: 42.86
Current: -156.05
-1218.1
42.86
ROC (Joel Greenblatt) (%) -2214.95
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. NVIV: -2214.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13352.31  Med: -1292.80 Max: 334.39
Current: -2214.95
-13352.31
334.39
EBITDA Growth (3Y)(%) -33.30
NVIV's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. NVIV: -33.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVIV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.2  Med: -33.30 Max: 543.1
Current: -33.3
-62.2
543.1
EPS Growth (3Y)(%) -32.30
NVIV's EPS Growth (3Y)(%) is ranked lower than
81% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. NVIV: -32.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVIV' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.2  Med: -32.30 Max: 544.7
Current: -32.3
-62.2
544.7
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 17.27
NVIV's P/B is ranked lower than
90% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. NVIV: 17.27 )
Ranked among companies with meaningful P/B only.
NVIV' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 67.4
Current: 17.27
0
67.4
Current Ratio 2.50
NVIV's Current Ratio is ranked lower than
69% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. NVIV: 2.50 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s 10-Year Current Ratio Range
Min: 0.14  Med: 1.45 Max: 14.81
Current: 2.5
0.14
14.81
Quick Ratio 2.50
NVIV's Quick Ratio is ranked lower than
64% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NVIV: 2.50 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s 10-Year Quick Ratio Range
Min: 0.14  Med: 1.45 Max: 14.81
Current: 2.5
0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.10
NVIV's Price/Net Cash is ranked lower than
80% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. NVIV: 20.10 )
Ranked among companies with meaningful Price/Net Cash only.
NVIV' s 10-Year Price/Net Cash Range
Min: 4.72  Med: 20.92 Max: 48
Current: 20.1
4.72
48
Price/Net Current Asset Value 18.94
NVIV's Price/Net Current Asset Value is ranked lower than
81% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. NVIV: 18.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 4.44  Med: 19.02 Max: 34.94
Current: 18.94
4.44
34.94
Price/Tangible Book 17.28
NVIV's Price/Tangible Book is ranked lower than
86% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. NVIV: 17.28 )
Ranked among companies with meaningful Price/Tangible Book only.
NVIV' s 10-Year Price/Tangible Book Range
Min: 3.83  Med: 14.90 Max: 29.7
Current: 17.28
3.83
29.7
Earnings Yield (Greenblatt) (%) -14.67
NVIV's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. NVIV: -14.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVIV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -29.4  Med: 0.00 Max: 1000
Current: -14.67
-29.4
1000

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Keynote... Sep 02 2015
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Keynote... Sep 02 2015
InVivo Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference Sep 01 2015
InVivo Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference Sep 01 2015
InVivo Therapeutics to Present at 2015 Tissue Engineering & Regenerative Medicine International... Aug 31 2015
InVivo Therapeutics to Present at 2015 Tissue Engineering & Regenerative Medicine International... Aug 31 2015
Day 6 of the Shanghai Saga-Time To Make a Shopping List of Cheap Stocks to Buy (4 Stocks) Aug 27 2015
InVivo Therapeutics to Present at the 17th Annual Spinal Research Network Meeting Aug 25 2015
InVivo Therapeutics to Present at the 17th Annual Spinal Research Network Meeting Aug 25 2015
InVivo Therapeutics Announces Listing Transfer to Nasdaq Global Market Aug 24 2015
InVivo Therapeutics Announces Listing Transfer to Nasdaq Global Market Aug 24 2015
InVivo Therapeutics Featured in Front Page Article in The Boston Globe Aug 24 2015
InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial Aug 20 2015
InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial Aug 20 2015
InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial Aug 20 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Aug 13 2015
InVivo Therapeutics’ CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business... Aug 13 2015
InVivo Therapeutics’ CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business... Aug 13 2015
InVivo Therapeutics Announces New Jersey’s Cooper Neurological Institute as New Clinical Site for... Aug 12 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Changes in Registrant's Certifying... Aug 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK